非清细胞癌的分子和治疗景观
Prerna R Nepali1, Ahmed Eraky1, Kennedy E Okhawere1
1Department of Urology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.
Nature reviews. Urology
|July 4, 2025
概括
非清细胞细胞癌 (nccRCC) 是一组多样化的癌,治疗指南有限. 分子生物标志物对于个性化治疗和改善这些罕见瘤的结果至关重要.
科学领域:
- 在瘤学瘤学.
- 生殖尿路病理学
- 翻译医学是一种翻译医学.
背景情况:
- 非清细胞细胞癌 (nccRCC) 包含具有独特临床和分子特征的多种组织学亚型.
- 目前对nccRCC的治疗指南由于异质性很大,因此受到限制,这给治疗带来了挑战.
- 虽然局部的nccRCC主要通过手术治疗,但转移性疾病的全身疗法显示出患者的反应是可变的.
研究的目的:
- 突出nccRCC的异质性和当前治疗策略的挑战.
- 强调分子生物标志物和诊断技术在管理nccRCC中的关键作用.
- 强调分子点在个性化治疗和优化罕见癌治疗结果方面的潜力.
主要方法:
- 对非清细胞细胞癌的当前临床和病理数据的审查.
- 在转移性nccRCC中对全身疗法反应的分析.
- 评估分子生物标志物,免疫组织化学和基因分析在nccRCC管理中的作用.
主要成果:
- nccRCC亚型表现出不同的遗传和分子特征,影响临床行为和治疗反应.
- 患者对免疫疗法,向疗法和化疗的可变反应突显了个性化方法的必要性.
- 分子生物标志物对于早期检测,预后和定制向疗法至关重要.
结论:
- 由于nccRCC的异质性,需要超出当前指南的量身定制的治疗策略.
- 分子分析的进步是改善nccRCC早期检测,预后和个性化治疗选择的关键.
- 确定可操作的分子标将增强临床决策,并优化罕见瘤患者的治疗反应.
更多相关视频
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.7K
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
9.1K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:06Renal Drug Clearance: Overview
345
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
345
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K